Statins in ischemic stroke: just low-density lipoprotein lowering or more?
BACKGROUND
Statins have been shown to improve the functional outcome of patients after an ischemic stroke. We hypothesized that daily statin intake improves functional outcome after an acute ischemic stroke in patients with low-density lipoprotein (LDL) less than or equal to 100 mg/dL.


METHODS
This was a prospective cohort study during a 22-month period of patients presenting with an acute ischemic stroke and lipid profiles measured. The functional disability was determined using modified Rankin scale score (0-2 good outcome, 3-6 bad outcome) at discharge. Chi-square test for binary data and nonparametric tests for nonnormally distributed variables were used for analysis.


RESULTS
Of 508 patients, 207 presented with an LDL of 100 mg/dL or less and were included in the analysis. There was no significant difference in admission stroke severity (National Institutes of Health Stroke Scale [NIHSS]; P = .18), age (P = .31), and sex (P = .06) between those taking statins and not taking statins. Patients with LDL less than or equal to 100 mg/dL and taking statins (n = 100) were significantly more likely to have a good functional outcome (odds ratio 1.91; 95% confidence interval 1.05-3.47) when compared with those not on the medication. After adjusting for age, sex, and NIHSS, statin intake still predicted a better functional outcome (P < .0001).


CONCLUSIONS
Daily statin intake appears to result in a better functional outcome after an ischemic stroke in patients with ideal LDL levels (<or=100 mg/dL) before and after adjusting for age and stroke severity. Pleiotropic effects of statins may play a role in this.
Stead
Latha G
LG
Department of Emergency Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA. Stead.Latha@mayo.edu
Vaidyanathan
Lekshmi
L
Kumar
Gautam
G
Bellolio
M Fernanda
MF
Brown
Robert D
RD
Suravaram
Smitha
S
Enduri
Sailaja
S
Gilmore
Rachel M
RM
Decker
Wyatt W
WW
D000368:Aged; D000369:Aged, 80 and over; D001921:Brain / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D001923:Brain Chemistry / Q000187:drug effects / Q000502:physiology; D002545:Brain Ischemia / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D002784:Cholesterol / Q000097:blood; D015331:Cohort Studies; D019610:Cytoprotection / Q000187:drug effects / Q000502:physiology; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D008077:Lipoproteins, LDL / Q000097:blood / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000494:pharmacology* / Q000627:therapeutic use; D011446:Prospective Studies; D020521:Stroke / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D016896:Treatment Outcome
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D008077:Lipoproteins, LDL; D018696:Neuroprotective Agents; D002784:Cholesterol